Shuttle Pharmaceuticals Holdings, Inc. (SHPH) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
One Research Court
Gaithersburg, MD 20850
United States of America (the)
Phone
240 403 4212
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
9
First IPO Date
August 31, 2022
| Name | Title | Pay | Year Born |
| Christopher Robert Cooper | Interim CEO & Director | 240,001 | 1970 |
| Milton Brown | Co-Founder | 4,167 | 1965 |
| Yuying Liang | Chief Financial Officer | 177,511 | 1991 |
| Tyvin A. Rich | Chief Clinical Officer & Chief Medical Officer | 218,000 | 1948 |
| Michael Vander Hoek | Vice President for Operations and Regulatory | 506,634 | 1960 |
| Mira Jung | Co-Founder & Chief Scientific Officer for Biology | 0 | 1949 |
Shuttle Pharmaceuticals Holdings, Inc., in conjunction with its subsidiary Shuttle Pharmaceuticals, Inc., is committed to the identification, advancement, and commercialization of pharmaceutical agents crafted to heighten the susceptibility of cancerous cells to radiation therapy. Its current portfolio of clinical-phase treatments features Ropidoxuridine, an orally administered halogenated pyrimidine, which is intended for individuals afflicted with brain tumors and soft tissue sarcomas. Additionally, the company is progressing Doranidazole, an injectable compound designed to make oxygen-deprived tumor cells more responsive to radiation, targeting malignancies of the pancreas, lungs, and liver. This enterprise was established in 2012 and maintains its principal operations in Rockville, Maryland.